United Therapeutics Corporation (UTHR) FY2026 Q2 P&L / Income Statement

United Therapeutics Corporation (UTHR) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue and costs use their disclosed categories.

Total revenues

783,300,000 US dollars

Cost of sales

99,500,000 US dollars

Gross profit (calculated)

683,800,000 US dollars

Operating expenses (calculated)

353,000,000 US dollars

Operating income

330,800,000 US dollars

Total other income, net

41,900,000 US dollars

Income before income taxes

372,700,000 US dollars

Income tax expense

39,700,000 US dollars

Net income

333,000,000 US dollars

Remodulin revenue

126,300,000 US dollars

Orenitram revenue

125,700,000 US dollars

Unituxin revenue

65,200,000 US dollars

Adcirca revenue

6,700,000 US dollars

Other revenue

6,800,000 US dollars

Tyvaso DPI revenue

326,600,000 US dollars

Nebulized Tyvaso revenue

126,000,000 US dollars

Remodulin cost of revenue

17,400,000 US dollars

Orenitram cost of revenue

6,100,000 US dollars

Unituxin cost of revenue

2,000,000 US dollars

Adcirca cost of revenue

3,000,000 US dollars

Other cost of revenue

11,000,000 US dollars

Tyvaso DPI cost of revenue

51,100,000 US dollars

Nebulized Tyvaso cost of revenue

8,900,000 US dollars

Research and development

146,300,000 US dollars

Selling, general, and administrative

206,700,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.